Drug file · From the Watchtower
Pembrolizumab: the briefings and the record
Every Prognyx briefing on pembrolizumab, newest first, and the dated events drawn from the sources those briefings cite. Rebuilt with each new briefing.
- Also known as
- Keytruda, MK-3475, KEYTRUDA QLEX
- Target, as briefed
- PD-1 checkpoint inhibitor + Nectin-4 antibody-drug conjugate
- Companies named
- Merck & Co., Pfizer, Astellas
- Prognyx coverage
- 3 briefings, 19 August 2026 to 21 October 2026
Prognyx briefings on pembrolizumab
- resectable muscle-invasive bladder cancer (perioperative)Keytruda-Padcev wins EU approval for resectable bladder cancer, any cisplatin status
The European Commission's 21 October clearance makes pembrolizumab plus enfortumab vedotin, per Merck, the EU's first PD-1-inhibitor-plus-ADC perioperative regimen for muscle-invasive bladder cancer without a cisplatin-eligibility restriction.
- adjuvant melanoma (recurrence-free and distant metastasis-free survival, INTerpath-001)Intismeran autogene improves RFS and DMFS in resected melanoma, Merck says
Merck and Moderna will present the first Phase 3 data for their personalized mRNA vaccine plus Keytruda at the ESMO 2026 Presidential Symposium, with Moderna already preparing for a potential launch.
- Resected high-risk melanoma (adjuvant setting)Merck and Moderna declare a Phase 3 melanoma win for intismeran autogene, per Endpoints News, Moderna's own filings had put the readout on the 2026 calendar
Endpoints News reports the personalized cancer vaccine succeeded in its first Phase 3; the endpoint detail comes from a joint release Prognyx could reach only through a news aggregator, while the primary records, a JCO five-year Phase IIb dataset and three Moderna 8-K exhibits, describe the programme around the result rather than its size.
Sourced timeline
Readouts, regulatory actions, filings, trial starts and deals that the Prognyx engine extracted from the documents cited in these briefings, newest first. Each links to its source and to the briefing that cited it. Press coverage is left out, and so is any event dated on its own briefing's day: the briefing above is the record for that day. A month without a day is a date the source gave only to the month.
- Regulatory actionFDA approval record for KEYNOTE-B15/EV-304 regimenFDA · cited in Keytruda-Padcev wins EU approval for resectable bladder cancer…
Registered trials on file
ClinicalTrials.gov records that the cited sources tie to pembrolizumab, each opening on the registry.
- NCT07840001 Neoadjuvant belzutifan +/- pembrolizumab in high-risk ccRCC
- NCT06868277 Rilvegostomig versus pembrolizumab in PD-L1-high NSCLC
- NCT06767514
- NCT06764875
- NCT06618287 BMS-986507 combinations in advanced solid tumors
- NCT06452277 Sevabertinib versus standard treatment in advanced NSCLC
- NCT06312176
- NCT06265025 GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
- NCT06047379 NEO212 in astrocytoma, glioblastoma or brain metastasis
- NCT05933577 INTerpath-001
The Watchtower, by email
The next move on pembrolizumab, the day it happens.
The next readout, FDA/EMA action or deal on pembrolizumab reaches you by email the day we publish it. One email per briefing, nothing else.
Double opt-in. Never sold, no open tracking. Privacy.
Get a free sample competitive brief on one of your assets, sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.
Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use. Event titles are written by the Prognyx engine from the linked source; the source is the record.